These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38968537)

  • 1. Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China.
    Yan J; Ding X; Wu J; Liu A; Fang L; Xu Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38759. PubMed ID: 38968537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital.
    Suárez Ferrer C; Martin-Arranz E; Martín-Arranz MD
    Gastroenterol Hepatol; 2024; 47(7):721-726. PubMed ID: 38219961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.
    Meng RP; Huang BB; Wei YL; Lyu L; Yang H; Liu C; Zhou HL; Liao XP; Zhou JY; Xie X
    J Dig Dis; 2024 Apr; 25(4):230-237. PubMed ID: 38764418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
    Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study.
    Kuo CJ; Le PH; Tai WC; Wu KL; Yen HH; Yen CW; Tung SY; Chung CS; Su MY; Chiu CT
    J Formos Med Assoc; 2022 Sep; 121(9):1689-1695. PubMed ID: 34924273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical efficacy and its influencing factors of vedolizumab in the treatment of ulcerative colitis].
    Lu JH; Fang LY; Cao SG; Ma GL; Xu Y; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2024 Oct; 104(39):3669-3675. PubMed ID: 39428216
    [No Abstract]   [Full Text] [Related]  

  • 8. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
    Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
    J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
    BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
    Narula N; Peerani F; Meserve J; Kochhar G; Chaudrey K; Hartke J; Chilukuri P; Koliani-Pace J; Winters A; Katta L; Shmidt E; Hirten R; Faleck D; Parikh MP; Whitehead D; Boland BS; Singh S; Sagi SV; Fischer M; Chang S; Barocas M; Luo M; Lasch K; Bohm M; Lukin D; Sultan K; Swaminath A; Hudesman D; Gupta N; Shen B; Kane S; Loftus EV; Siegel CA; Sands BE; Colombel JF; Sandborn WJ; Dulai PS
    Am J Gastroenterol; 2018 Sep; 113(9):1345. PubMed ID: 29946178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
    Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
    Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis.
    Sablich R; Urbano MT; Scarpa M; Scognamiglio F; Paviotti A; Savarino E
    Sci Rep; 2023 Feb; 13(1):1816. PubMed ID: 36725872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
    Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.
    Huang K; Liu J; Xia W; Tian C; Yao L; Cao Q; Chen H
    Front Pharmacol; 2023; 14():1188751. PubMed ID: 37214457
    [No Abstract]   [Full Text] [Related]  

  • 17. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis.
    Kakiuchi T; Yoshiura M
    Clin Ther; 2022 Jul; 44(7):1028-1032. PubMed ID: 35779956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab for the treatment of ulcerative colitis.
    Stallmach A; Schmidt C; Teich N
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
    Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
    Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.